

**Psychological outcomes of 12-15-year-olds with gender dysphoria  
receiving pubertal suppression: assessing reliable and clinically  
significant change**

Susan McPherson<sup>a\*</sup> and David E.P. Freedman<sup>b</sup>

<sup>a</sup> *School of Health and Social Care, University of Essex, Colchester CO4 3SQ, UK;*

<sup>b</sup> *Independent Researcher, London, UK*

\*Corresponding author:

Professor Susan McPherson, School of Health and Social care, University of Essex,

Colchester, UK, [smcpher@essex.ac.uk](mailto:smcpher@essex.ac.uk)

## **Psychological outcomes of 12-15-year-olds with gender dysphoria receiving pubertal suppression: assessing reliable and clinically significant change**

### **Abstract (200)**

The evidence base for psychological benefits of GnRHA treatment for adolescents with gender dysphoria (GD) has been deemed “low quality” by the UK National Institute of Health and Care Excellence, limitations including inattention to clinical importance of findings. This secondary analysis of UK clinical study data uses Reliable and Clinically Significant Change approaches to fill this gap in the evidence. The original uncontrolled study collected data within a specialist GD service. Participants were 44 12-15-year-olds diagnosed with GD. Puberty was suppressed using “triptorelin”; participants were followed-up for 36 months. Secondary analysis used data from the parent-report Child Behaviour Checklist and the Youth Self-Report forms. Reliable change results: 15-34 percent of participants reliably deteriorated depending on the subscale and time point. Clinically significant change results: 37-58 percent were in the borderline or clinical range at baseline (depending on scale). Of these, rates of clinically significant change were low and fell to zero at endpoints on both self-report and parent-report. The approach offers an established complementary method to analyse individual level change and to examine who might benefit or otherwise from treatment in a field where research designs have been challenged by lack of control groups and low sample sizes.

Keywords: gender dysphoria; GnRHA; psychological outcomes; UK; clinical significance

## **Introduction**

The UK Gender Identity Development Service (GIDS) was established in 1989 providing therapeutic assessment and psychological intervention for children and young people experiencing gender dysphoria (GD). An early audit of the service found that of the first 124 referrals to the service, the majority had complex social and/or psychological difficulties in addition to gender dysphoria (Di Ceglie, Freedman, McPherson, & Richardson, 2002). At that time, GIDS was based on a psychotherapeutic service model based within an NHS specialist mental health Trust in London. When children reached adulthood (at least 16) and wanted to pursue medical interventions such as puberty blockers, cross-sex hormones or surgery, they would be referred to adult services in a hospital setting.

Puberty blockers (GnRHa treatment) are a form of medical intervention, licenced for use to retard puberty in young people with precocious puberty, that have additionally been prescribed for people experiencing GD, previously restricted to those aged 16 years and over. The intervention had been trialled on younger children in the Netherlands since the late 1990s (Cohen-Kettenis & van Goozen, 1998). From around 2009 a number of countries including USA and Australia began to permit its use in this younger age group (Carmichael et al., 2021a). In 2009 the British Society of Endocrinology and Diabetes published a statement advocating their use in a cautious and carefully managed way, monitored within a research context (Barnes, 2023).

Also in 2009, the service commissioning structure at the UK specialist GD service changed from a London based service receiving extra-contractual referrals on a case-by-case basis to a nationally commissioned specialist service (Barnes, 2023). Referrals began to rapidly increase from 2009 to 2019, while levels of complex social and psychological difficulties in the client group remained high (Holt, Skagerberg, &

Dunsford, 2016). Controversy concerning referrals for puberty blockers in this service has been ongoing since 2011 when treatment was first offered to 12-15-year-olds taking part in research and subsequently offered routinely from 2014. The main argument for the introduction of puberty blockers in the UK for this age group had been their potential to relieve psychological distress.

*“A key purpose of GnRHa treatment is to pause puberty, to avoid a deterioration in wellbeing and allow for further exploration of a young person’s feelings about their gender identity and their wishes for the future, without the pressure or distress which may come from further unwanted bodily changes”*

(Gender Identity Development Service, n.d.)

However, in a high-profile case, the UK High Court ruled in 2020 that under 16s could not legally consent to puberty blockers, a decision later overturned by the Court of Appeal, decisions which led to ongoing disruptions and uncertainty for patients and families. In June 2023, NHS England announced it would no longer provide puberty blockers outside of research.

To inform an ongoing NHS review of services in this area, the UK’s National Institute for Health and Care Excellence (NICE) published an evidence review (NICE, 2020) on “Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria”. Using GRADE methodology to assess study quality, the majority of evidence was deemed to provide “very low” certainty across a wide range of outcomes including mental health, quality-of-life, bone density and cognitive function. The review followed standard methodologies employed by NICE for identifying evidence, appraising methodological quality and synthesising outcomes.

In relation to mental health and psychosocial outcomes (the focus of the present study), the review summarised outcomes from three studies. These were two

prospective longitudinal studies (Costa et al., 2015; de Vries, Steensma, Doreleijers, & Cohen-Kettenis, 2011) and one cross-sectional study (Staphorsius et al., 2015). One of these was a study of 70 teenagers which found statistically significant reduction in depression; no statistically significant impact on anger or anxiety; statistically significant improvements on internalising and externalising problems measured by the Child Behaviour Checklist (CBCL) and Youth Self Report Form (YSR); and statistically significant improvement in global functioning measured by the Children's Global Assessment Scale (CGAS) (de Vries et al., 2011). Another found no improvements on CGAS scores among 201 teenagers over 6 months (Costa et al., 2015). The cross-sectional study (Staphorsius et al., 2015) involved 40 adolescents but the NICE review concluded that the analysis of CBCL outcomes was unclear.

The NICE review noted that the studies reviewed were generally “not reliable and changes could be due to confounding, bias or chance” (NICE, 2020). Common issues include lack of comparison or control groups, small samples, poor reporting of physical and mental comorbidities and concomitant treatments, variability and poor reporting of ages children started treatment, unclear analyses and, in particular, little interpretation of clinical significance of findings, the latter being the focus of the current study.

In 2021, after the publication of the NICE review, the UK research group reported results of psychological outcomes over 3 years (Carmichael et al., 2021a). However, unlike previous research groups, the data was made available through the UK Data Archive, reflecting current good practice in clinical outcomes research. This provides a unique opportunity to address the concern raised by the NICE review that studies of psychological outcomes in this field have omitted to assess clinically meaningful change.

The UK study received ethical approval from the UK National Research Ethics Service in 2011 and recruitment of participants took place from 2011 to 2014 (Carmichael et al., 2021a). The aims of the study were “to evaluate the benefits and risks for physical and mental health and wellbeing of mid-pubertal suppression in adolescents with GD; to add to the evidence base regarding the efficacy of GnRHa treatment for young people with GD; and to evaluate continuation and discontinuation of GD and the continued wish for gender reassignment within this group”. The study assessed physical response to pubertal suppression; bone health; adverse events; and psychological outcomes. Psychological outcomes included general psychopathology, self-harm, quality of life, body image, GD, general functioning and patient experience. General psychopathology was assessed using the CBCL (parent-report) and YSR (self-report). These are validated measures that have been widely used internationally to assess children’s mental health (Achenbach & Rescorla, 2001) and were used by two of the studies reviewed by NICE. These measures are arguably the most reliable indicator of general mental health and psychological functioning among the outcomes assessed in the study and because of available psychometric properties and normative data, are amenable to analysis of Reliable and Clinically Significant Change.

Data from the GIDS study were lodged at the UK Data Archive (Carmichael et al., 2021b) and can be downloaded for researcher use without any further additional ethical approval required. The aim of the current study was therefore to re-analyse the data from the GIDS study to assess Reliable and Clinically Significant Change on the CBCL and YSR for the sample at 12, 24 and 36 months follow-up.

## **Materials and Methods**

### ***Design***

The current study is a secondary analysis of data collected at the UK GIDS service and stored at the UK Data Archive. The design of the current study is an assessment of individual level change using Reliable and Clinically Significant Change analysis (Jacobson & Truax, 1991). The original study was an uncontrolled pre-post design.

### ***Participants***

In the original study, children meeting the eligibility criteria were referred by GIDS to University College London Hospital NHS Foundation Trust between 2011-2014, where study information was given and consent taken. Eligibility criteria were: age 12-15; seen by GIDS for at least 6 months; at least 4 assessment sessions in GIDS; psychologically stable; meeting criteria for GD (including high likelihood of extreme psychological distress with ongoing pubertal development); actively requesting GnRHA; capacity for informed consent; established puberty; and normal endocrine function. Forty-four children consented to take part in the study. Detailed study procedures and exclusion criteria are provided in the published paper (Carmichael et al., 2021a). Participants completed the YSR at baseline (n=44), 12 months (n=41) and 24 months (n=15). Parents completed the CBCL at baseline (n=43), 12 months (n=41), 24 months (n=20) and 36 months (n=11). All of the data available for these measures were included in the current analysis.

### ***Measures***

The data deposited were standardised for age and sex and included individual level scores for CBCL Externalising, CBCL Internalising, CBCL Total Problems, YSR

Externalising, YSR Internalising and YSR Total Problems. These sub-scales are “higher-order” subscales which combine other subscales into broad dimensions (Achenbach & Rescorla, 2001). The Internalising domain is considered a measure of general emotional problems including anxiety, depression, somatic complaints and being withdrawn. The Externalising domain is considered an aggregate scale of behavioural problems including attention problems and aggressive behaviour. The Total Problems score is considered an aggregate of emotional and behavioural problems as well as sleep difficulties (Guerrera et al., 2019). The scales have published psychometric properties including good internal reliability with Chronbach alphas ranging from 0.90 to 0.97 (Achenbach & Rescorla, 2001). The scales come from a broad system of measures (ASEBA) developed in the USA which have been widely used with published norms and reliability data and clinical cut-offs for all versions. Established cut-points are <60 (normal range), 60-63 (borderline range) and >63 (clinical range) (Achenbach & Rescorla, 2001).

### ***Reliable and Clinically Significant Change analysis***

Comparing group averages using statistical tests is widely used in psychology experiments and outcome studies of clinical interventions. However, used alone in clinical research, the approach can be misleading. Finding a “statistically significant” difference between two average scores can lead people to believe that the difference (or lack of difference) is important in clinical terms (Field, 2013). Reporting effect sizes is one important additional statistic in clinical studies that helps determine the clinical significance of a result. However, like statistical significance of mean differences, the effect size still relies on group averages. Looking only at group averages and comparing them masks variation. Analysis of Reliable and Clinically Significant Change (Jacobsen & Truax, 1991) is an established complementary approach in clinical research which



allows us to understand more about what is happening for individuals in a group rather than only what is happening “on average” for the whole group.

Analysing “reliable change” and “clinically significant change” (Blampied, 2022) uses the logic of individual change in which the number of people in the study does not influence whether the results are “statistically significant”. The approach relies on known psychometric features of the questionnaire being used, such as how reliable it is when used with similar groups of patients with similar problems and how it performs statistically in people with and without symptoms. Many people will have taken part in prior testing of the questionnaire to establish these features and properties, as is the case with the CBCL and YSR (Achenbach & Rescorla, 2001). Information about the questionnaire is used to provide parameters for analysis of individual change without requiring a minimum sample size for power or statistical significance.

The approach enables analysis of individual change within the group, rather than averaging out scores across the group which is a fairly narrow way to interpret results from clinical studies. Rather than saying "on average" there was a statistically significant difference before and after treatment; we can say "of the whole sample, 50% improved but 50% deteriorated" and so on. As such, evaluation of both adult and child psychological services in the UK use approaches which examine data at the level of individual change rather than group means (Gibbons, Harrison, & Stallard, 2021; Wolpert et al., 2016). These approaches typically assess two aspects of individual change: Reliable Change and Clinically Significant Change, the latter sometimes referred to as “recovery”.

Reliable Change is individual change that is sufficiently unlikely to have arisen by measurement error alone. The approach provides summary information about what proportion of the sample improve, deteriorate or stay the same (no change). The formula

takes into account the standard error of difference (before and after treatment) as well as the internal reliability of the measure (Evans, Margison, & Barkham, 1998). The analysis is “applicable, in one form or another, to the measurement of change on any continuous scale for *any* clinical problem”(Evans et al., 1998). The approach can be used with clinical outcome data whether as part of a controlled or uncontrolled research study, or as part of routine outcome evaluation in a clinical setting. Clinically significant change or “recovery” refers to the proportion of patients who are within the clinical or borderline range at baseline, show reliable improvement and move into a non-clinical range (Gibbons et al., 2021; Jacobson & Truax, 1991).

The Reliable Change Index (RCI) for each sub-scale was calculated using the formula provided by Evans, Margison and Barkham using Chronbach alpha as the reliability criterion (Evans et al., 1998). Using the RCI, we calculated the proportion of participants in each of the three categories: No change, Deteriorate, Improve.

Clinically significant change (“recovery”) was calculated using the published clinical cut-points. Following Gibbons, Harrison and Stallard (2021), participants who scored in the borderline or clinical range at baseline (greater than or equal to 60) were included in the analysis of clinically significant change. Of those meeting this criterion, we calculated the proportion who had moved into the normal range at each time point.

### ***Ethics***

Data from the original study were anonymised and lodged at the UK Data Archive in a format suitable for use with no further ethical approval or consent required, as agreed with the Health Research Authority (Carmichael et al., 2021b). Please see the original publication for more detailed information on study methodology and further details on the ethics approval which was obtained from the National Research Ethics Service (NRES: reference 10/H0713/79) in February 2011 (Carmichael et al., 2021a).

Subsequently, the team had discussions with the Health Research Authority who provided permission for data to be deposited with the UK Data Archive on the condition that sensitive data was removed to minimise disclosure risk of personal information (Carmichael et al., 2021a).

## **Results**

The findings for Reliable Change and Clinically Significant Change are presented below by Internalising Problems (Table 1), Externalising Problems (Table 2) and Total Problems (Table 3). [Insert Tables 1, 2 and 3]

### ***Reliable Change***

Data indicate that across all scales with both self-report (YSR) and parent report (CBCL), the majority of participants experience no reliable change in distress across all time points. Between 15% and 34% deteriorate and between 9% and 20% reliably improve.

### ***Clinically Significant Change***

As indicated in Tables 1, 2 and 3, there are relatively small numbers of participants in the clinical range at baseline for all subscales: roughly 40-60% of the overall sample, depending on the scale. Rates of reliable recovery range from 0% to 45% depending on the scale and time point. **All scales fell to zero percent showing clinically significant change at the final time point with the exception of CBCL Externalising scale which shows 20% had moved into the normal range at 36 months.**

## **Discussion**

The original report of the GIDS study found no statistical differences on the CBCL or YSR between time points, concluding that either puberty blockers “brought no measurable benefit nor harm to psychological function”; or that “treatment reduced [the] normative worsening of problems”. The latter conclusion is based on evidence that psychological problems as measured by the YSR and CBCL tend to worsen during early adolescence, which is one way to interpret the findings. However, the evidence cited comes from non-clinical populations (Verhulst, 2003). Children who attend GIDS are a clinical population (Di Ceglie et al., 2002; Holt et al., 2016), with a similar range of social and psychological problems to those seen in CAMHS populations. Moreover, the children in the GIDS study were receiving mental health support from the GIDS service in a therapeutic setting, making them a clinical population by definition. Therefore, an alternative benchmark to consider is the UK CAMHS population rather than non-clinical populations. When evaluating CAMHS services in the UK, it is standard practice to examine individual level change using Reliable and Clinically Significant Change methods and to benchmark interpretations against CAMHS psychological outcomes.

This is the first analysis of UK data on children aged 12-15 with GD taking puberty blockers demonstrating individual level change as opposed to testing differences between group averages. As such this analysis gives a fuller picture of the benefits and risks of treatment. However, the analysis is limited by absence of UK norms for the measures used combined with the lack of a study control group to provide local norms; clinical cut points used were based on US normative data and it is possible that UK teenagers may present differently to US teenagers in respect of GD. The

analysis is also limited by the limitations of the dataset available for re-analysis which lacks differentiation by sex and item level data to look at more fine grained sub-scales.

Nevertheless, this secondary analysis of Reliable and Clinically Significant Change of the UK GIDS data indicates that, broadly speaking, for Internalising and Externalising Problems, 56%-68% experience no reliable change in distress across time points and although there is some variation, proportions do not appear markedly different between self-report and parent-report. Between 15% and 29% deteriorate; and between 9% and 20% reliably improve. The Total Problems scale shows higher proportions deteriorating (20%-34% depending on time point).

A rate of around 20% reliable improvement is not dissimilar to other CAMHS service evaluations. For example, using a similar global scale of psychopathology (RCADS), Gibbons, Harrison and Stallard (Gibbons et al., 2021) found between 20.7% and 24.4% of their sample reliably improved. However, the same study found that nearly all the remaining participants showed No Change with only a very small proportion (0.7% - 5.7%) deteriorating. These proportions were similar for a range of other psychological outcome variables used (Gibbons et al., 2021). Comparatively high levels of deterioration in the GIDS sample (ranging from 15-34%) is therefore concerning. It is important to note that the highest rate of deterioration (34%) is seen in the self-report scale at 12 months and only slightly reduces by 24 months to 27%.

Relatively few participants fell into the borderline or clinical range at baseline (27%-58% depending on the scale). This is lower than a typical CAMHS population; Gibbons, Harrison and Stallard (2021) found around 90% of their sample to be in the clinical or borderline range at baseline. This suggests that the GIDS participants may have been less distressed when they were referred to the clinic than typical CAMHS

referrals and may indicate a relatively low referral threshold operating at the time period studied.

Given the relatively low proportion of the sample in the clinical or borderline range, the rates of clinically significant change should be treated with caution. Nevertheless, a notable finding is that there is a tendency for parent-report and self-report to show a discrepancy at first, with self-report scores indicating a higher rate of clinically significant change after 12 months (around 25-45%). However, this discrepancy reduces over time so that at the later measurement points, self-report and parent-report rates of clinically significant change converge at zero, **with the exception of CBCL externalising which shows 20% (1/5) moved to the normal range at 36 months**. CAMHS services typically see rates of clinically significant change around 50% (Gibbons et al., 2021) and therefore the rates seen in the GIDS sample are comparatively low, particularly given the rates **mostly** fall to zero over a prolonged period (3 years).

Using the reliable and clinically significant change approach to analysis of clinical study data provides an opportunity for research teams in this field to conduct fuller analysis of their data to ascertain whether there are any variables which might predict which children with GD are most likely to benefit psychologically and which are most likely to deteriorate, rather than considering the group as uniform in likely response to treatment. Statistical significance testing relies on minimum sample sizes which have been difficult to obtain in this field to date. This complementary analytic approach allows us to look at how a treatment is performing in terms of the percentage of patients improving, deteriorating and showing clinically significant change. It is possible, using this approach, to look at patterns, such as who is benefitting and who is not. For example, the approach could be used to look more closely at biological sex in

order to say, for example, that "x% of biological boys improved"; "x% of biological girls deteriorated"; "x% of biological boys experienced side effect A" and so on, which would improve consent processes. Many studies in this field have small sample sizes, limiting statistical testing within groups by sex. Using analysis of individual change to observe patterns like this would be useful to guide further research, help inform parents and children more clearly, and lead to more individualised, personalised care. The approach could also enable comparisons in the absence of formal control groups which have been considered unethical. For example, it would be possible to analyse routinely collected outcome data for children who do not take up puberty blockers to generate comparable data on Reliable and Clinically Significant Change as a naturalistic control group. We recommend that these approaches be incorporated into new GD services being established in the UK as well as new research studies being designed.

## References

- Achenbach, T. M., & Rescorla, L. A. (2001). *Manual for the ASEBA School-Age Forms & Profiles*. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families.
- Barnes, H. (2023). *Time to Think: The Inside Story of the Collapse of the Tavistock's Gender Service for Children*. London: Swift Press.
- Blampied, N. M. (2022). Reliable change and the reliable change index: still useful after all these years? *The Cognitive Behaviour Therapist*, 15, e50.  
<https://doi.org/10.1017/S1754470X22000484>
- Carmichael, P., Butler, G., Masic, U., Cole, T. J., De Stavola, B. L., Davidson, S., ... Viner, R. M. (2021a). Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. *PLOS ONE*, 16(2),

e0243894. <https://doi.org/10.1371/journal.pone.0243894>

Carmichael, P., Butler, G., Masic, U., Cole, T. J., De Stavola, B. L., Davidson, S., ... Viner, R. M.

(2021b). *Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK 2019-2021 [Data Collection]*. <https://doi.org/10.5255/UKDA-SN-854413>

Cohen-Kettenis, P. T., & van Goozen, S. H. M. (1998). Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. *European Child & Adolescent Psychiatry*, 7(4), 246–248. <https://doi.org/10.1007/s007870050073>

Costa, R., Dunsford, M., Skagerberg, E., Holt, V., Carmichael, P., & Colizzi, M. (2015).

Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria. *The Journal of Sexual Medicine*, 12(11), 2206–2214. <https://doi.org/10.1111/jsm.13034>

de Vries, A. L. C., Steensma, T. D., Doreleijers, T. A. H., & Cohen-Kettenis, P. T. (2011). Puberty Suppression in Adolescents With Gender Identity Disorder: A Prospective Follow-Up Study. *The Journal of Sexual Medicine*, 8(8), 2276–2283. <https://doi.org/10.1111/j.1743-6109.2010.01943.x>

Di Ceglie, D., Freedman, D., McPherson, S., & Richardson, P. (2002). Children and adolescents referred to a specialist gender identity development service: Clinical features and demographic characteristics. *International Journal of Transgenderism*, 6(1).

Evans, C., Margison, F., & Barkham, M. (1998). The contribution of reliable and clinically significant change methods to evidence-based mental health. *Evidence-Based Mental Health*, 1(3), 70–72. <https://doi.org/10.1136/ebmh.1.3.70>

Field, A. (2013). *Discovering Statistics Using IBM SPSS Statistics* (4th ed.). Sage Publications Ltd.

Gender Identity Development Service. (n.d.). The Early Intervention Study. Retrieved from



<https://gids.nhs.uk/research/early-intervention-study>

Gibbons, N., Harrison, E., & Stallard, P. (2021). Assessing recovery in treatment as usual provided by community child and adolescent mental health services. *BJPsych Open*, 7(3), e87. <https://doi.org/10.1192/bjo.2021.44>

Guerrera, S., Menghini, D., Napoli, E., Di Vara, S., Valeri, G., & Vicari, S. (2019). Assessment of Psychopathological Comorbidities in Children and Adolescents With Autism Spectrum Disorder Using the Child Behavior Checklist. *Frontiers in Psychiatry*, 10. <https://doi.org/10.3389/fpsy.2019.00535>

Holt, V., Skagerberg, E., & Dunsford, M. (2016). Young people with features of gender dysphoria: Demographics and associated difficulties. *Clinical Child Psychology and Psychiatry*, 21(1), 108–118. <https://doi.org/10.1177/1359104514558431>

Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. *Journal of Consulting and Clinical Psychology*, 59(1), 12–19. <https://doi.org/10.1037/0022-006X.59.1.12>

National Institute for Health and Care Excellence. (2020). *Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria*. Retrieved from [https://cass.independent-review.uk/wp-content/uploads/2022/09/20220726\\_Evidence-review\\_GnRH-analogues\\_For-upload\\_Final.pdf](https://cass.independent-review.uk/wp-content/uploads/2022/09/20220726_Evidence-review_GnRH-analogues_For-upload_Final.pdf)

Staphorsius, A. S., Kreukels, B. P. C., Cohen-Kettenis, P. T., Veltman, D. J., Burke, S. M., Schagen, S. E. E., ... Bakker, J. (2015). Puberty suppression and executive functioning: An fMRI-study in adolescents with gender dysphoria. *Psychoneuroendocrinology*, 56, 190–199. <https://doi.org/10.1016/j.psyneuen.2015.03.007>

Wolpert, M., Jacob, J., Napoleone, E., Whale, A., Calderon, A., & Edbrooke-Childs, J. (2016). *Child- and Parent-Reported Outcomes and Experience from Child and Young People's*

*Mental Health Services 2011–2015*. Retrieved from

[https://www.corc.uk.net/media/1544/0505207\\_corc-report\\_for-web.pdf](https://www.corc.uk.net/media/1544/0505207_corc-report_for-web.pdf)

Table 1. CBCL and YSR Internalising Scales – reliable change and reliable recovery

<b><u>CBCL Internalising</u></b>				<b><u>YSR Internalising</u></b>		
Reliable change	12m	24m	36m	Reliable change	12m	24m
No change	68%	60%	64%	No change	56%	67%
Deteriorate	20%	20%	27%	Deteriorate	29%	20%
Improve	12%	20%	9%	Improve	15%	13%
N	41	20	11	N	41	15
Clinical/borderline range at baseline	Reliable and Clinically Significant Change*			Clinical/borderline range at baseline	Reliable and Clinically Significant Change*	
24/43	2/22	1/11	0/6	20/44	3/17	0/3
56%	9%	9%	0%	45%	18%	0%

\*Denominator is number of paired cases for the relevant time point which were in the borderline or clinical range at baseline

Table 2. CBCL and YSR Externalising Scales – reliable change and reliable recovery

<b><u>CBCL Externalising</u></b>				<b><u>YSR Externalising</u></b>		
Reliable change	12m	24m	36m	Reliable change	12m	24m
No change	66%	70%	64%	No change	61%	67%
Deteriorate	15%	15%	18%	Deteriorate	22%	20%
Improve	20%	15%	18%	Improve	17%	13%
N	41	20	11	N	41	15
Clinical/borderline range at baseline	Reliable and Clinically Significant Change*			Clinical/borderline range at baseline	Reliable and Clinically Significant Change*	
16/43	4/15	1/9	1/5	12/44	2/11	0/2
37%	27%	11%	20%	27%	18%	0%

\*Denominator is number of paired cases for the relevant time point which were in the borderline or clinical range at baseline

Table 3. CBCL and YSR Total Scales

<b><u>CBCL Total</u></b>				<b><u>YSR Total</u></b>		
Reliable change	12m	24m	36m	Reliable change	12m	24m
No change	49%	60%	55%	No change	37%	60%
Deteriorate	29%	20%	18%	Deteriorate	34%	27%
Improve	22%	20%	27%	Improve	29%	13%
N	41	20	11	N	41	15
Clinical/borderline range at baseline	Reliable and Clinically Significant Change			Clinical/borderline range at baseline	Reliable and Clinically Significant Change	
25/43	4/23	2/11	0/5	19/44	6/17	0/3
58%	17%	18%	0%	43%	35%	0%

\*Denominator is number of paired cases for the relevant time point which were in the borderline or clinical range at baseline